Publications by authors named "Thomas D Szucs"

Claim this Profile
[
[Tattoo ink between beauty and risk: regulation in Switzerland, the EU and the USA].
Thomas D Szucs

Ther Umsch· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022.
Xiaofang Zhang, Carl C Peck, Yaning Wang, Thomas D Szucs, Wan Sun

BMC Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The knowledge of medical law among medical students and medical service providers in Switzerland].
Katja Meier, Thomas D Szucs

Ther Umsch· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Medicine and Law: an Introduction - Part 2].
Thomas D Szucs

Ther Umsch· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Medicine and Law: an Introduction - Part 1].
Thomas D Szucs

Ther Umsch· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.
Helena Aebersold, Fabienne Foster-Witassek, Stefanie Aeschbacher, Juerg H Beer, Eva Blozik, Thomas D Szucs

Open Heart· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort.
Helena Aebersold, Miquel Serra-Burriel, Fabienne Foster-Wittassek, Giorgio Moschovitis, Stefanie Aeschbacher, Thomas D Szucs

Heart· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of cardiovascular events with traditional risk equations and total plaque area of carotid atherosclerosis: The Arteris Cardiovascular Outcome (ARCO) cohort study.
Michel Romanens, Ansgar Adams, Isabella Sudano, Waldemar Bojara, Sandor Balint, Thomas D Szucs

Prev Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Breast cancer drug approvals by the US FDA from 1949 to 2018.
Chandra P Leo, Cornelia Leo, Thomas D Szucs

Nat Rev Drug Discov· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
Chandra P Leo, Bettina Hentschel, Thomas D Szucs, Cornelia Leo

Cancers (Basel)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer drug approvals by the US FDA from 1949 to 2018.
Chandra P Leo, Cornelia Leo, Thomas D Szucs

Nat Rev Drug Discov· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venous Thromboembolism and Renal Impairment: Insights from the SWIss Venous ThromboEmbolism Registry (SWIVTER).
David Spirk, Tim Sebastian, Martin Banyai, Jürg H Beer, Lucia Mazzolai, Thomas D Szucs

Semin Thromb Hemost· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of symptomatic iron deficiency - a survey among Swiss women.
Patricia R Blank, Yuki Tomonaga, Thomas D Szucs, Matthias Schwenkglenks

BMC Womens Health· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Thomas D Szucs

Ther Umsch· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer.
Thomas D Szucs, Kevin P Szillat, Eva Blozik

Pharmgenomics Pers Med· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory watch: Structural and procedural characteristics of international regulatory authorities.
Anand B Jain, Annette Mollet, Thomas D Szucs

Nat Rev Drug Discov· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Patricia R Blank, Thomas D Szucs

Praxis (Bern 1994)· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The enigma of value: in search of affordable and accessible health care.
Thomas D Szucs, Martina Weiss, Guido Klaus

Eur J Health Econ· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herpes zoster vaccine: A health economic evaluation for Switzerland.
Patricia R Blank, Zanfina Ademi, Xiaoyan Lu, Thomas D Szucs, Matthias Schwenkglenks

Hum Vaccin Immunother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutrition and health--Why payors should get involved.
Thomas D Szucs, Alexander W Stoffel

Nutrition· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
Florian S Gutzwiller, Alena M Pfeil, Zanfina Ademi, Patricia R Blank, Peter G Braunhofer, Thomas D Szucs

Pharmacoeconomics· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Christof Vulsteke, Alena M Pfeil, Charlotte Maggen, Matthias Schwenkglenks, Ruth Pettengell, Thomas D Szucs

Breast Cancer Res Treat· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory watch: Efficiency indicators for new drugs approved by the FDA from 2003 to 2013.
Rossella Belleli, Roland Fisch, Thomas D Szucs

Nat Rev Drug Discov· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Patricia R Blank, Martin Filipits, Peter Dubsky, Florian Gutzwiller, Michael P Lux, Thomas D Szucs

Pharmacoeconomics· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the potential annual welfare impact of innovative drugs in use in Switzerland.
Matea Pavic, Alena M Pfeil, Thomas D Szucs

Front Public Health· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis